MVP Development Complete: What is Next

We have reached a major milestone: our MVP is complete. Here is what we have built and our roadmap for the next 12 months.

What We Have Built

As of Q3 2025, HeAIth's core foundation is in place:

AI Diagnostic Engine

  • Generates differential diagnoses from presenting complaints
  • Recommends appropriate initial investigations
  • Flags red-flag symptoms requiring urgent attention

Clinical Interface

  • Fast symptom input system for busy consultations
  • Clear output format with clinical reasoning
  • Mobile-responsive for tablets and laptops

Technical Infrastructure

  • GDPR-compliant data architecture
  • HL7 FHIR ready for NHS integration
  • Sub-second response times

What We Have Learned

Accuracy vs. Comprehensiveness

Early versions generated too many differentials (30+ for chest pain). We refined the algorithm to show 8-12 clinically relevant possibilities based on prevalence and severity.

Clinical Reasoning Matters

Clinicians want to understand why the AI suggests each diagnosis. We added explainability features showing which symptoms drive each differential.

Speed is Critical

In 10-minute consultations, every second counts. We optimised response times to under 2 seconds to assist rather than hinder workflow.

What is Missing

Our MVP is functional but not finished. We still need clinical validation, bias testing, NHS interoperability, and regulatory compliance.

This is where you come in. We are recruiting clinical advisors to guide this next phase.

Roadmap: The Next 12 Months

Q4 2025: Advisory Board Formation

  • Recruit 3-5 founding clinical advisors
  • Establish governance structure

Q1 2026: Product Refinement & Regulatory Foundations

  • Algorithm improvements based on clinical feedback
  • ISO 13485 QMS implementation begins
  • Clinical Safety Officer appointment

Q1-Q2 2026: Seed Funding Round

  • Target raise: £500k-700k
  • Focus: regulatory compliance, clinical validation, product development

Q2-Q3 2026: Clinical Validation & MHRA Submission

  • Multi-site clinical validation studies
  • MHRA UKCA submission (Class IIb SaMD)
  • Target MHRA market authorisation Q3 2026

Why We are Transparent About What is Not Ready

Many healthcare AI companies claim their products are "ready" when they are not. We are taking a different approach: radical transparency.

HeAIth is not yet approved for clinical use and will not be until Q3 2026 at the earliest. We are showing you the MVP to demonstrate feasibility and invite collaboration.

This honesty builds trust and sets realistic expectations about the 12-18 month regulatory pathway ahead.

Join Us on This Journey

MVP complete is a milestone, but it is just the beginning. The next 12 months will determine whether HeAIth becomes a valuable clinical tool.

We need your expertise to make this work.

Join Our Advisory Board Request a Demo